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Drugs that target platelet function have a prominent role in
the prevention and treatment of cardiovascular occlusive
disease, and acetylsalicylic acid, or aspirin, is likely the most
widely used. First synthesized by Felix Hoffman in 1897,
a chemist at Farbenfabriken Friedrich Bayer & Co., the
compound was initially used for pain relief; its utility for the
prevention of myocardial infarction emerged beginning in
the middle of the 20th century (1,2). The 1971 discovery of
its principal mechanism of action, irreversible acetylation of
cyclooxygenase and inhibition of thromboxane A2 produc-
tion, won the Nobel Prize for Sir John Vane in 1982 (3).
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Since that time, aspirin has proved its value and cost-
effectiveness in the secondary prevention of major adverse
cardiovascular events in a remarkably broad range of patients,
including smokers, the elderly, obese, patients with hyper-
tension, and those with diabetes, as reviewed recently by
Hennekens and Baigent (4) and Hennekens and Dalen (5).
The data for myocardial infarction are compelling, with a 23%
reduction in total mortality when aspirin is given within the
ﬁrst 24 h of symptom onset (6). However, despite docu-
mented efﬁcacy, the use of aspirin in primary prevention is
limited by a lack of data about optimal dosages and individual
risk versus beneﬁt, information that is critical to the use of any
drug in low-risk or intermediate-risk populations.
Amajor concern surrounding the use of aspirin is that some
people (reports claim anywhere from 2% to >50%) may be
resistant to its antiplatelet action. These ﬁgures are based on
results with point-of-care clinical testing and laboratory-based
assays measuring platelet aggregation responses and serum
thromboxane A2 levels (7,8). Looked at in another way, the
relatively high rate of on-treatment myocardial infarction
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relevant to the contents of this paper to disclose.this resistance may be due to noncompliance with therapy,
malabsorption, up-regulation of alternative aggregation me-
chanisms, or competition for the cyclo-oxygenase 1 active site
by coadministered nonsteroidal anti-inﬂammatory agents
(9–13). Genetic variations, especially in cyclo-oxygenase 1
and cyclo-oxygenase 2, have been linked to a poor on-therapy
platelet response (14), but the predictive value of these single-
nucleotide polymorphisms for patients remains to be deter-
mined, and their individual contributions to risk are likely to
be small. Whatever the cause, aspirin-resistant patients are
less likely to obtain therapeutic beneﬁt from aspirin, while
still experiencing its side effects of gastrointestinal distress
and bleeding. Badly needed are tools that could determine the
risk/reward ratio before starting aspirin in an otherwise
healthy subject and thereby provide a guide to proper dosing.
Recent advances in genomic technology have allowed
clinical investigators to look beyond standard functional
tests and protein assays for signs of disease at the level of the
genome. While the deoxyribonucleic acid sequence is
essentially ﬁxed and identical in all cell types, the activity of
each gene is controlled differently in each cell, in a dynamic
and reversible manner, through so-called epigenetic mech-
anisms (see Lorenzen et al. [15] for an excellent review).
Protein-coding messenger ribonucleic acid (mRNA) levels
are a direct readout of gene activity and as such can be
highly responsive to environmental cues, disease states, and
drug effects. From a technical point of view, measurement of
mRNAs is rapid, speciﬁc, and sensitive; even very rare
mRNAs can be detected and quantiﬁed in specially preserved
whole blood using polymerase chain reaction assays (16).
The entire population of mRNAs in a sample (the “tran-
scriptome”) can be assayed using deoxyribonucleic acid
microarray hybridization and increasingly by an emerging
technology called ribonucleic acid sequencing (RNASeq)
(17,18) that can provide both quantitation and ribonucleic
acid sequence information. A number of groups have
exploited gene expression proﬁling to identify biomarkers of
disease and to obtain clues as to how patients may respond to
drugs or to other interventions (19–22).
In a study reported in this issue the Journal, Voora et al.
(23) used whole-blood gene expression proﬁling to identify
mRNA patterns that predict the therapeutic response to
aspirin, ﬁnding that these same patterns are predictive of
myocardial infarction risk and death in 2 cohorts of patients
with known coronary artery disease, independent of other
risk factors. Demonstrating just how widely used and
effective aspirin is, it appears from this study that resistance
to aspirin creates a particular hazard for patients with
coronary artery disease.
An important factor in the success of this project is that it
began with a well-deﬁned biological response. Using a novel
platelet function score, a composite of 4 different functional
assays, the investigators were able to develop a robust readout
of therapeutic response to aspirin and link this to gene
expression patterns of biological relevance at the very begin-
ning of the study. They then reproduced these expression
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artery disease. This study design provides mechanistic in-
sight speciﬁcally into the aspirin response, ﬁltering out factors
related to baseline platelet function as well as atherosclerosis
per se.
Microarrays generate vast amounts of data that can be
challenging to analyze. The challenge is to take that haystack
of data and ﬁnd the few needles that really track with the
biology of interest. Here, the subsequent bioinformatic
analysis involved several steps. First, the investigators iden-
tiﬁed the entire pool of mRNAs that changed depending on
the presence of an aspirin response and then looked for
groups of mRNAs that changed in tandem (in the same
direction, by the same amount, at the same time) and that
were therefore presumably regulated by the same upstream
factors. Next, they looked for clues to those regulatory
factors by searching for recurring functional motifs in these
sets of genes. This process generated multiple sets of
mRNAs (which the investigators call factors), each uniﬁed
by function and regulation, that could then be tested for
regulation in the 2 validation cohorts. The relative expres-
sion of each mRNA within the set was totaled to arrive at
a quantitative factor score that can be used in multivariate
analyses. Only 1 factor, a group of 60 mRNAs, emerged
from this analysis to show a robust correlation with aspirin
response in both validation studies and in the subsequent
CATHGEN cohort.
Interestingly, although perhaps not surprisingly, this
group of genes, which the investigators term the aspirin
response signature (ARS), appears to be highly reﬂective of
platelet function. Twenty-four of 60 genes were found to be
speciﬁc to platelets or megakaryocytes. Six platelet proteins
encoded by mRNAs in the ARS also correlated with aspirin
response. Hence, the ARS appears to be conveying an im-
portant message about platelet biology in the presence of
aspirin. ITGA2B, the principal component, encodes the
glycoprotein IIb half of the platelet glycoprotein IIb/IIIa
complex, an important drug target during interventions for
acute coronary syndrome (24). However, this gene signature
is not merely a platelet microarray; two-thirds of the ex-
pressed transcripts are not obviously of platelet origin. It will
be interesting to learn more about the biological roles of
additional mRNAs within the ARS, which may give other,
unexpected clues to the biology of aspirin resistance.
There are some unavoidable limitations of this well-devised
study. One is that it was based on a platelet function score
devised by the investigators that may not be indicative of
clinically relevant aspirin resistance. Each of the individual
methods for testing platelet function that were combined
to produce this score has limited reproducibility (7). In addi-
tion, no single test is sufﬁcient to test the full range of
platelet functions, as multiple cyclo-oxygenase-dependent and
cyclo-oxygenase-independent pathways regulate platelet ad-
hesion, aggregation, and granule release (25). Most important,
no existing platelet function tests can reliably predict which
patients will have myocardial infarctions while taking aspirin.Any selection bias in favor of patients with recent athero-
thrombotic activity (e.g., samples collected in the cardiac
catheterization laboratory) may lead to an overestimation of
basal platelet reactivity and a spurious conclusion of aspirin
failure (8). The study design and multiple validation sets have
largely mitigated these concerns. Importantly, the ARS stands
alone as a genome-based test for myocardial infarction risk,
independent of the functional platelet tests with which it
correlates.
Other limitations include the preponderance of Cauca-
sians in the CATHGEN test population (26); eventually,
the value of the ARS will need to be proven in larger, more
ethnically and geographically diverse groups. It will be
important to determine how newer antiplatelet and antico-
agulant agents affect the ARS. Just as important, the utility
of the test in the presence of common comorbidities (e.g.,
uncontrolled diabetes, acute inﬂammation, and platelet
dyscrasias) will need to be veriﬁed. Overall, however, this
study has moved us closer to having a much-needed and
hitherto elusive predictor of the clinical efﬁcacy of aspirin.
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